bioAffinity Technologies

bioAffinity Technologies, Inc. has developed diagnostics and therapies to detect and treat cancer at the cellular level, addressing the critical need for early cancer detection and treatment. The company's first product, CyPath® Lung, a flow cytometry test for lung cancer, has been licensed to Precision Pathology Services for ongoing development and commercial sale as a laboratory-developed test.